Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer

NCT01083615 is registered in ClinicalTrials.gov with Achieve Life Sciences as lead sponsor.

NCT NCT01083615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01083615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Lead sponsor
Achieve Life Sciences
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2010
Completion date
March 31, 2013
Enrollment
14 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

castrate-resistant prostate cancer, hormone refractory prostate cancer